Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Marc Kamin, MD
SK Life Science, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
121 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Centro de Educacion Medica E Investigaciones Clinicas (cemic)
Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina
- Hogar de Dia Casa Jesi
Buenos Aires, Argentina
- Instituto de Neurociencias de Fundacion Favaloro
Buenos Aires, Argentina
- Flinders Medical Centre
Bedford Park, Australia
- Eastern Health, Box Hill Hospital
Box Hill, Australia
- Royal Prince Alfred Hospital
Camperdown, Australia
- Strategic Health Evaluators
Chatswood, Australia
- Monash Medical Centre
Clayton, Australia
- St. Vincent'S Hospital Melbourne
Fitzroy, Australia
- Austin Health Melbourne Brain Centre
Heidelberg, Australia
- Royal Brisbane & Women'S Hospital
Herston, Australia
- Alfred Health - the Alfred Hospital
Melbourne, Australia
- Melbourne Health (the Royal Melbourne Hospital)
Parkville, Australia
- Prince of Wales Hospital
Randwick, Australia
- Westmead Hospital
Westmead, Australia
- Multiprofile Hospital for Active Treatment Puls Ad
Blagoevgrad, Bulgaria
- First Multiprofile Hospital for Active Treatment- Sofia Ead
Sofia, Bulgaria
- Multiprofile Hospital for Active Treatment of Neurology and Pschiatry "sv. Naum" Ead
Sofia, Bulgaria
- University Multiprofile Hospital for Active Treatment Aleksandrovska Ead
Sofia, Bulgaria
- Centro Neuropsicologia Ltda.
La Florida, Santiago Metropolitan, Chile
- Complejo Asistencial Dr. Sotero del Rio
Puente Alto, Santiago Metropolitan, Chile
- Hospital Base Valdivia
Valdivia, Chile
- Fakultni Nemocnice U Sv. Anny V Brne
Brno, Czechia
- Affidea Praha S.R.O.
Prague, Czechia
- Fakultni Nemocnice V Motole
Prague, Czechia
- Krankenhaus Mara Ggmbh - Epilepsiezentrum Bethel
Bielefeld, Germany
- University of Bonn, Department of Epileptology
Bonn, Germany
- Epilepsiezentrum Kork
Kehl, Germany
- Universitätsmedizin Der Johannes Gutenberg-Universität Mainz
Mainz, Germany
- Universitätsklinikum Gießen Und Marburg Gmbh
Marburg, Germany
- Universitätsklinikum Münster, Klinik Fur Neurologie Mit Institut Fur Translationale Neurologie-Epileptologie
Münster, Germany
- Országos Klinikai Idegtudományi Intézet
Budapest, Hungary
- Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz
Debrecen, Hungary
- Bacs Kiskun Megyei Korhaz
Kecskemét, Hungary
- Neurociencias Estudios Clinicos S.C.
Culiacán, Mexico
- Grupo Medico Camino S.C.
Mexico City, Mexico
- Human Science Research Trials S. de R.L. de C.V.
Mexico City, Mexico
- Centro de Investigacion Grupo Vitamagen
Monterrey, Mexico
- Clinical Research Institute S.C.
Tlalnepantla, Mexico
- Centrum Neurologii Krzysztof Selmaj
Lodz, Lódzkie, Poland
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Aug 2016
- Primary completion
- 31 Mar 2021
- Completion
- 7 Feb 2022
- Last update posted
- 14 May 2024
- Registered enrollment
- 1,345
- Registry id
- NCT02535091
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.